In immunosuppression therapy: MALIGNANCIES AND SERIOUS INFECTIONS, KIDNEY GRAFT THROMBOSIS; NEPHROTOXICITY
In heart transplantation: MORTALITY
See full prescribing information for complete boxed warning.
- TRADE NAMES: Afinitor (Novartis); Certican (Novartis); Zortress (Novartis)
- INDICATIONS: Prophylaxis of organ rejection in adults following kidney or liver transplant; advanced renal cell carcinoma; neuroendocrine tumors of pancreatic, gastrointestinal or lung origin; breast cancer in post-menopausal women with advanced hormone-receptor positive, HER2-negative type cancer; renal angiomyolipoma and tuberous sclerosis complex; subependymal giant cell astrocytoma associated with tuberous sclerosis
- CLASS: Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Immunosuppressant, mTOR inhibitor
- HALF-LIFE: ~30 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Aprepitant, Atazanavir, Atorvastatin, Benazepril, Captopril, Clarithromycin, Clozapine, Conivaptan, Cyclosporine, Darunavir, Delavirdine, Digoxin, Efavirenz, Enalapril, Erythromycin, Grapefruit Juice, Indinavir, Itraconazole, Ketoconazole, Lapatinib, Lisinopril, Live vaccines, Nelfinavir, Oxcarbazepine, Phenytoin, Posaconazole, Quinapril, Ramipril, Ribociclib, Rifampin, Rifapentine, Ritonavir, Saquinavir, St John's Wort, Telithromycin, Venetoclax, Verapamil, Viloxazine, Voriconazole
- See adverse reactions attributed to class:
Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor)
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of everolimus in kidney transplantation in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 08/07/2024
